ライフサイエンスコーパス: safety concern

1 tly excised using Cre/Lox system for vaccine safety concern.

2 tional studies have addressed this important safety concern.

3 n aniline, a structural motif of prospective safety concern.

4 interactions translates into a considerable safety concern.

5 There was no safety concern.

6 s offer the potential to assess this patient safety concern.

7 s represents an important ambulatory patient safety concern.

8 es in animal-derived foods are a global food safety concern.

9 rations in liver or kidney function or other safety concern.

10 ly reporting of the study results because of safety concerns.

11 .S. market for cosmetic use in 1992 owing to safety concerns.

12 Both drugs were well tolerated with no safety concerns.

13 nd those widely used in livestock have major safety concerns.

14 tal HIV infection; a dose that has not shown safety concerns.

15 potential therapy for GBM is limited due to safety concerns.

16 e activities after flushing because of water safety concerns.

17 study, with comparable efficacy and no late safety concerns.

18 ficiency, lack of cell-specific targeting or safety concerns.

19 hich time recruitment was suspended owing to safety concerns.

20 vention, but cautious use is essential given safety concerns.

21 argeable batteries is associated with severe safety concerns.

22 ed for children under 2 or asthmatics due to safety concerns.

23 ability to address individual end points or safety concerns.

24 anti-inflammatory drugs (NSAIDs) could pose safety concerns.

25 We did not identify any new safety concerns.

26 ucceeded owing to the lack of efficacy or to safety concerns.

27 t, ivacaftor was well tolerated, with no new safety concerns.

28 latory frameworks, clinical experiences, and safety concerns.

29 Treatments were well tolerated with no safety concerns.

30 us rituximab and was not associated with new safety concerns.

31 of autologous CDCs did not raise significant safety concerns.

32 There were no safety concerns.

33 ssociated with patient compliance issues and safety concerns.

34 Results The study was stopped early owing to safety concerns.

35 re efficient treatment of diseases and fewer safety concerns.

36 esuscitation is not warranted due to serious safety concerns.

37 mmended for use in young children because of safety concerns.

38 o twice-daily tacrolimus capsules and no new safety concerns.

39 ness, unacceptable levels of tolerability or safety concerns.

40 as well tolerated, and presented no apparent safety concerns.

41 There were no safety concerns.

42 after the second interim analysis because of safety concerns.

43 ients with multiple sclerosis (MS) with some safety concerns.

44 ain-derived vaccines (JE-MB) associated with safety concerns.

45 led to enhanced efficacy with no unexpected safety concerns.

46 Atorvastatin was well tolerated without safety concerns.

47 ts with implanted cardiac devices because of safety concerns.

48 been better in terms of efficiency but have safety concerns.

49 ative blood transfusions are costly and have safety concerns.

50 ectroporation without integration-associated safety concerns.

51 ng of myocardial infarction due to long-term safety concerns.

52 n MTX-resistant patients, with no unexpected safety concerns.

53 induces vascular tumours, raising important safety concerns.

54 There were no major safety concerns.

55 No drug has demonstrated safety concerns.

56 ms in MTX-naive patients, with no unexpected safety concerns.

57 e immunoevasive properties of VV have raised safety concerns.

58 There were no safety concerns.

59 censed for human use because of efficacy and safety concerns.

60 exponentially and evolve additional patient safety concerns.

61 continued abruptly or inappropriately due to safety concerns.

62 nce from communities, and prolonged regional safety concerns.

63 orticoids, have limited efficacy and present safety concerns.

64 R was well tolerated by all patients without safety concerns.

65 s in previous MC1R ligand development raises safety concerns.

66 nt 2G-TKI yields promising TFR rates without safety concerns.

67 es for individual drugs, without significant safety concerns.

68 een associated with RBC transfusion, raising safety concerns.

69 industrial chemical with health and product safety concerns.

70 o lead to undesirable side effects and major safety concerns.

71 such as fingolimod have been weighed down by safety concerns.

72 patients after a safety analysis because of safety concerns.

73 ically well-defined heterointerfaces without safety concerns.

74 There were no safety concerns.

75 the first trimester of pregnancy because of safety concerns.

76 the rate of uncommon or rare side effects or safety concerns.

77 ts with multiple sclerosis but has potential safety concerns.

78 ium plating on the graphite surface, raising safety concerns.

79 PSPs than with a known change in efficacy or safety concerns.

80 a dose-dependent manner, without significant safety concerns.

81 There were no vaccine- or CHMI-related safety concerns.

82 People appear to walk for transport despite safety concerns.

83 We noted no serious safety concerns (114 [35%] patients in the dronabinol gr

84 A composite of (1) withdrawals due to safety concerns, (2) FDA issuance of incremental boxed w

85 255 incidents, which were classified as 132 safety concerns (51.8%), 102 nonsafety-related quality c

86 literature suggest that there are three main safety concerns: (a) to prevent biological or neural dam

87 lendar year (before/after February 2008 when safety concerns about intensive glucose control were rep

88 uni strains with human gangliosides presents safety concerns about the development of Guillain-Barre

89 erm ovarian function and pregnancies and the safety concerns about the potential negative interaction

90 The findings support current safety concerns about the use of these drugs in older ad

91 The results raise potential safety concerns about the use of vectors encoding the E4

92 n and the resulting immunodeficiency prompts safety concerns about their use.

93 and Monitoring Board because of futility and safety concerns after 85 patients were randomized.

94 We did not identify any safety concerns after PPV in our patients with dense non

95 the near future for human and environmental safety concerns against hazardous VOCs.

96 potentially affected represents an important safety concern and requires an immediate change in pract

97 F patients with renal dysfunction because of safety concerns and a lack of evidence of their effectiv

98 l care physicians understand the principles, safety concerns and appropriate management of patients u

99 Treatment with desmoteplase did not cause safety concerns and did not improve functional outcome w

100 We identified no new safety concerns and few patients discontinued treatment

101 and mossy metal deposits, leading to serious safety concerns and low Coulombic efficiency during char

102 after the second interim analysis because of safety concerns and low efficacy.

103 bility of medications, and also presents new safety concerns and monitoring requirements with which p

104 ocols (i.e. empirical dosing, driven by both safety concerns and practical aspects).

105 bition to improve outcomes further, minimize safety concerns and provide more convenient means of adm

106 To mitigate safety concerns and simplify reaction execution, an HF-f

107 ing tissue-specific transcription has raised safety concerns and suggested that attempts should be ma

108 ability and efficacy of outcomes, as well as safety concerns and the cost-to-benefit ratio were also

109 The safety concerns and the lack of market success of these

110 n has been reported in adults, there were no safety concerns and the overall bone and renal safety pr

111 The interventions did not raise any safety concerns and there were no differences between gr

112 There were no new or long-term safety concerns and tolerability was similar across grou

113 h approach has potential advantages but also safety concerns and unresolved questions.

114 tients with MVR is not yet established, with safety concerns and very few outcome data.

115 dapivirine ring was not associated with any safety concerns and was associated with a rate of acquis

116 ucial part of assessment of possible vaccine safety concerns and will help to separate legitimate saf

117 nce rate within 42 days after vaccination (a safety concern) and beyond 42 days; hazard ratios estima

118 olecule agents, pharmacokinetic limitations, safety concerns, and a complex regulatory environment.

119 development to improve performance, address safety concerns, and fulfil regulatory obligations is re

120 Therapies are limited by efficacy, safety concerns, and multiple daily dosing.

121 There were no unexpected safety concerns, and the results support the continued d

122 USP <797> standards, radiation safety concerns, and work-flow patterns were the focal p

123 use, parental perceptions that vaccines pose safety concerns are affecting vaccination rates, particu

124 An examination of how potential safety concerns are being navigated with compounds curre

125 ware interface to ensure that the three main safety concerns are closely monitored.

126 adoption in critical applications increases, safety concerns are resurfacing due to the inherent flam

127 No infective safety concerns arose during 447 person years of follow-

128 No safety concerns arose during either microdialysis or sca

129 No new safety concerns arose over this extended follow-up.

130 areas for future research include addressing safety concerns associated with genetic labels and devel

131 Safety concerns associated with long-acting beta2-agonis

132 his single-device approach, coupling-related safety concerns associated with multiple conductor appro

133 represents a potential strategy to avoid the safety concerns associated with replication-competent va

134 This study further addresses safety concerns associated with the potential use of pre

135 The study was interrupted owing to safety concerns associated with the three-drug regimen.

136 ials have been concluded, showing no notable safety concerns associated with the use of phage.

137 To address safety concerns associated with this vector, we develope

138 However, safety concerns associated with viral vector production

139 ain iPS and ES cell pluripotency without the safety concerns associated with xenoculture.

140 quired pressure ulcers are a serious patient safety concern, associated with poor patient outcomes an

141 The evidence of efficacy without obvious safety concerns at 8 weeks of follow-up motivates human

142 ernative vaccine approach because of reduced safety concerns compared with live vaccines.

143 enuated HSV vaccines predicated on unfounded safety concerns currently limits their widespread accept

144 -a]quinolines on multigram scale without any safety concerns due to the reaction's inherent exothermi

145 ion-competent viral vectors pose significant safety concerns due to vector pathogenicity.

146 There were no safety concerns during the follow-up period.

147 nsistently improved immune responses, and no safety concerns emerged in the context of IIV-HD revacci

148 Recent safety concerns enforced the search for alternative ultr

149 Safety concerns, falls with severe injury, managing chan

150 fects of the Cas9 nuclease represent a major safety concern for any therapeutic application.

151 However, the SEM features raise safety concerns for capsular integrity after FLACS and w

152 ve potential benefits, but they also present safety concerns for human health.

153 ata, we did not detect any new or unexpected safety concerns for MMR vaccination in adults.

154 gies on the inherently toxic IL-2 has raised safety concerns for patients, justifying a search for al

155 There are also considerable safety concerns for PSCs related to their potential for

156 This causes serious safety concerns for state-of-the-art lithium-ion batteri

157 definitively shows that there are no special safety concerns for their administration in CKD.

158 pe as one strategy to potentially circumvent safety concerns from earlier derivatives such as in vitr

159 oncerns and will help to separate legitimate safety concerns from events that are temporally associat

160 Safety concerns >1 year from implantation have been rais

161 rect-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity.

162 Nevertheless, safety concerns have limited its widespread use in human

163 thritis and also might reduce pain; however, safety concerns have limited the use of general MAP kina

164 reatments for SSSIs caused by MRSA; however, safety concerns have limited use of these agents.

165 ficile infection, but practical barriers and safety concerns have prevented its widespread use.

166 Persistent safety concerns have stalled the development of viable h

167 Beyond microbiological safety, concerns have been raised regarding contaminatio

168 resses resistance but is hampered by serious safety concerns, hepatotoxicity in particular.

169 b for between 3.5 and 5.6 years, with no new safety concerns, highlighting the feasibility of long-te

170 rin and 152 placebo) because of futility and safety concerns identified by the Data Safety Monitoring

171 ion criteria was well tolerated, with no new safety concerns identified over 2 years.

172 The treatment was well tolerated with no safety concerns identified.

173 idiabetic drugs have limited efficacy and/or safety concerns, identifying new medicinal agents, such

174 ailed to offer incremental benefit or raised safety concerns (ie, hypotension).

175 n of PERV-inactivated animals to address the safety concern in clinical xenotransplantation.

176 r-a-go-go-related gene]) channel are a major safety concern in drug development.

177 tem (CNS) disease and has emerged as a major safety concern in multiple sclerosis patients treated wi

178 To assess whether HBV-R is a safety concern in patients receiving HCV DAAs.

179 s B virus reactivation is a newly identified safety concern in patients with HBV-HCV co-infection tre

180 inal (GI) perforation has emerged as a novel safety concern in relation to medications used to treat

181 Immunogenicity is a critical safety concern in the development of any protein therape

182 Empirical studies did not identify safety concerns in the USA, Canada, the EU, and Japan, w

183 e greatest efficiency, they also raise major safety concerns including carcinogenesis and immunogenic

184 However, the critical safety concern is the neurotropic nature conveyed by the

185 ussion of molecular diagnostics and possible safety concerns is also provided.

186 Modest efficacy, intolerance, and safety concerns limit current antiarrhythmic drugs.

187 ic inflammation, but lack of selectivity and safety concerns limit development.

188 However, safety concerns limit the use of iodinated and gadoliniu

189 into oblivion for several decades because of safety concerns, metallic Li is now ready for a revival,

190 Due to health and safety concerns, most wireless power transfer (WPT) sche

191 However, there has been safety concern of SPIONs with cirrhosis related to exces

192 opularity, questionable efficacy claims, and safety concerns of e-cigarettes so that they may counsel

193 ul activation domains without the associated safety concerns of integrating viral vectors.

194 Safety concerns of the currently available inhibitors ha

195 These results highlight safety concerns of using low concentrations of DMSO as a

196 nd medication use without raising unexpected safety concerns, offering a minimally invasive surgical

197 aberrant disulfide bonds and could result in safety concerns or decreased efficacy.

198 was discontinued in any research arm showing safety concerns or insufficient evidence of activity (la

199 serin was well tolerated with no significant safety concerns or worsening of motor function.

200 rix extracts, such as Matrigel, which raises safety concerns over the use of these products.

201 However, two safety concerns persist: endonuclease-associated adverse

202 Safety concerns pertaining towards fungal occurrence and

203 gree of missed alarm events suggests patient safety concerns posed by hospital-level transmission sys

204 conducted original data analysis; considered safety concerns, potential benefits, research, and poten

205 n lead to regaining of its virulence creates safety concerns precluding many vaccines from clinical a

206 within Antarctic sea ice where navigational safety concerns prevent ships from surveying.

207 However, safety concerns prevent the development of attenuated hu

208 HZ/su was well-tolerated, with no safety concerns raised within 1 month post-dose 2.

209 Safety concerns regarding corneal thickness were taken i

210 Safety concerns regarding first-generation drug-eluting

211 However, there are still knowledge gaps and safety concerns regarding stem cell-based therapies.

212 However, safety concerns regarding target expression on healthy t

213 d influenza virus vaccines (LAIV), there are safety concerns regarding the possibility of reassortmen

214 This work addresses some of the safety concerns regarding the potential use of predatory

215 f research in this arena, and discussions on safety concerns regarding the use of dental nanomaterial

216 ed effects of poor immune responsiveness and safety concerns regarding the use of live attenuated vac

217 These findings do not support safety concerns related to surgeons operating the night

218 smission often exclude pregnant women due to safety concerns related to the drugs.

219 However, safety concerns related to the inability to control CAR-

220 Furthermore, no safety concerns related to the novel platinum chromium a

221 In this review we aim to discuss some of the safety concerns related to the use of immunosuppressive

222 transplantation is shown to be effective but safety concerns remain.

223 ordings (r=0.63 [95% CI 0.53-0.79]), with no safety concerns reported.

224 ice, regulation of repackaged medication for safety concerns should also consider the evaluation of t

225 There were no clear safety concerns specific to people with CKD but availabl

226 In addition to being a safety concern, substantial ribavirin dose reductions ha

227 ed with no unexpected or clinically relevant safety concerns, supporting further testing.

228 Safety concerns surround the use of long-acting beta-ago

229 ion of permanently engineered T cells raises safety concerns that have hampered testing of this appro

230 and requires further refinement to alleviate safety concerns that include stroke.

231 monkey images for several reasons, including safety concerns that limited the light levels permissibl

232 become more important because of increasing safety concerns that recombinant erythropoietin therapy

233 therapeutics, despite modest efficacy, have safety concerns that underscore the need for effective p

234 optimised methodology was applied to assess safety concerning the content of PAHs in white and parbo

235 Citing serious safety concerns, the data monitoring committee terminate

236 nerally well tolerated with no signals for a safety concern; there were no serious adverse events (AE

237 n-derived product, limited availability, and safety concerns, this treatment option has essentially b

238 models and uncover potential diagnostic and safety concerns to be overcome as tankyrase inhibitors a

239 onstrated excellent efficacy without serious safety concerns to date.

240 ill also need to be further improved and any safety concerns understood to provide the necessary impe

241 magnetic resonance imaging (MRI) because of safety concerns, unless the devices meet certain criteri

242 the past 15 to 20 yrs and presents a patient safety concern unlike any other in the intensive care un

243 reater antitumor activity without additional safety concerns versus ipilimumab.

244 No safety concern was identified at doses up to 16 mg per k

245 No consistent evidence of safety concerns was identified.

246 Despite demonstrating no safety concerns, we conclude that patients with subarach

247 No safety concerns were apparent at 1 year.

248 No safety concerns were associated with spirometry.

249 e was identified, and 17 for which potential safety concerns were found.

250 No safety concerns were identified after systemic administr

251 No safety concerns were identified after the ingestion of g

252 No safety concerns were identified at any of the dose level

253 No new safety concerns were identified for ceftazidime-avibacta

254 No safety concerns were identified for FF or FP.

255 No safety concerns were identified in this short-term study

256 No new safety concerns were identified in this study.

257 after US licensure of TIV-HD, no new serious safety concerns were identified in VAERS.

258 of participants enrolled in these trials, no safety concerns were identified with passive immunizatio

259 more reactogenic than placebo, but no major safety concerns were identified.

260 No safety concerns were identified.

261 No major safety concerns were identified.

262 No safety concerns were identified.

263 No safety concerns were identified.

264 No safety concerns were identified.

265 No unexpected safety concerns were identified.

266 blockers in addition to study drugs, and no safety concerns were identified.

267 No new or long-term safety concerns were identified.

268 hen the vaccines were coadministered, and no safety concerns were identified.

269 l tolerated in this young population; no new safety concerns were identified.

270 d in previous RCTs, and no new or unexpected safety concerns were identified.

271 No overall safety concerns were identified.

272 In this small study, no safety concerns were identified; however, transient feve

273 No safety concerns were noted during the 3-year follow-up.

274 No safety concerns were noted with an intravenous dose of A

275 INTERPRETATION: No new safety concerns were noted with eltrombopag and the tria

276 No major safety concerns were noted, with low rates of procedural

277 erolimus remained well-tolerated, and no new safety concerns were noted.

278 No new safety concerns were noted.

279 No major safety concerns were noted.

280 No safety concerns were noted.

281 lar efficacy and safety profiles, and no new safety concerns were noted.

282 cine was well tolerated, and no dose-related safety concerns were observed.

283 No safety concerns were observed.

284 No new safety concerns were observed.

285 No safety concerns were observed.

286 No safety concerns were raised for either active treatment.

287 No safety concerns were raised in any age group.

288 r glycemic therapy deintensified, even after safety concerns were raised in the ACCORD trial.

289 No safety concerns were raised with IIV-HD revaccination.

290 No new safety concerns were reported.

291 Known safety concerns were validated, including elevated non-f

292 We found no evidence of any safety concerns when this vaccine was administered durin

293 er, stent thrombosis (ST) emerged as a major safety concern with first-generation DES early after the

294 These trials showed no serious safety concerns with current modalities.

295 We identified no safety concerns with either vaccine: seven (8%) of 91 pa

296 Safety concerns with erythropoietin analogues and intrav

297 There were no major safety concerns with high-dose RS compared with low-dose

298 Given potential safety concerns with the use of heparin, 0.9% sodium chl

299 Conversely, there were no safety concerns with very low LDL-cholesterol concentrat

300 ough canned food consumption are an emerging safety concern worldwide.